Journey Medical

What Journey Medical does

Journey Medical Corporation is a commercial-stage pharmaceutical company headquartered in Scottsdale, Arizona, that develops and markets a portfolio of FDA-approved prescription drugs for dermatological conditions. The company, founded in 2015 and majority-owned by Fortress Biotech (approximately 36% equity stake), trades on Nasdaq under the ticker DERM and markets nine branded prescription products across rosacea (Emrosi), primary axillary hyperhidrosis (Qbrexza), severe recalcitrant nodular acne (Accutane), acne (Amzeeq, Targadox), fungal skin infections (Zilxi, Exelderm), and skin wounds (Luxamend). Emrosi (DFD-29), a low-dose oral minocycline approved by the FDA in November 2024 and commercially launched in April 2025, is the flagship growth asset, having generated $14.7M in net revenues across its first nine months and approximately 53,000 prescriptions filled.

The company operates a dermatology-focused sales force targeting dermatologists and healthcare professionals through direct field detailing, alongside a Patient Savings Program designed to expand patient access to its medications. Distribution flows through traditional retail and specialty pharmacy channels, with payer access negotiated through three major Group Purchasing Organizations (GPOs) covering approximately 85% of U.S. commercial lives (over 150 million). Revenue is generated through prescription sales reimbursed by health insurers and managed care organizations, with FY2025 total revenue of $61.9M (10% YoY growth) and Q1 2026 revenue of $16M (+21% YoY). Gross margins reached 66.2% in FY2025 and the company achieved positive adjusted EBITDA of $2.9M.

The portfolio reflects an efficient small-team commercial model (11-50 employees) that commercializes products originated through Fortress Biotech's pipeline and partnerships. The company holds compliance certifications aligned with California Health & Safety Code §119400-119402, HHS OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and the PhRMA Code on Interactions with Healthcare Professionals. Strategic priorities include launching 1-2 incremental niche dermatology products in the second half of 2026 and expanding the commercial team by up to five additional sales representatives, while managing securities fraud investigations by Pomerantz LLP and Johnson Fistel following a March 25, 2026 earnings disclosure that Emrosi prescription demand was outpacing reported revenue.

Name

Journey Medical

Legal name

Journey Medical Corporation

Website

https://journeymedicalcorp.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Journey Medical Corporation is a commercial-stage pharmaceutical company that markets nine FDA-approved prescription dermatology drugs — including rosacea treatment Emrosi, hyperhidrosis drug Qbrexza, and Accutane — to dermatologists and patients in the United States through a focused field sales force and pharmacy distribution.

Ownership category

akta.pro rank

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Supply Chain, Technology or R&D, Operations

Revenue model

1. Product Sales: Journey Medical generates revenue through the sale of FDA-approved prescription dermatology products. The company markets nine branded FDA-approved prescription drugs including Emrosi for rosacea, Qbrexza for hyperhidrosis, Accutane for severe acne, and others. Revenue is generated through prescriptions filled at pharmacies with reimbursement from health insurance plans and managed care organizations.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Journey Medical Corporation is a commercial-stage pharmaceutical company that develops, markets, and sells a portfolio of FDA-approved prescription dermatology products addressing rosacea, primary axillary hyperhidrosis, severe nodular acne, acne, fungal skin infections, and skin wounds. The company commercializes its products through a dermatology-focused sales force that engages prescribers, supported by Group Purchasing Organization (GPO) contracts delivering broad payer coverage and a Patient Savings Program that expands patient access.

Product overview

Journey Medical Corporation is a commercial-stage pharmaceutical company operating as a single brand portfolio of FDA-approved prescription dermatology products. The company markets eight branded FDA-approved prescription drugs addressing common skin conditions including rosacea (Emrosi), primary axillary hyperhidrosis (Qbrexza), severe nodular acne (Accutane), acne (Amzeeq, Targadox), fungal skin infections (Zilxi, Exelderm), and skin wounds (Luxamend). The company commercializes these products through a dermatology-focused sales force and maintains a patient savings program to expand access. The portfolio is concentrated on dermatological treatments, with Emrosi serving as the primary growth driver following its April 2025 commercial launch.

Differentiator

Problem solved

Functional benefit

Brands

• Emrosi: FDA-approved oral rosacea treatment (DFD-29), a low-dose minocycline product launched in April 2025 for treating inflammatory lesions of rosacea.
• Qbrexza
• Accutane
• Amzeeq
• Zilxi
• Luxamend
• Exelderm
• Targadox

Products and services

• Emrosi (DFD-29) Oral, low-dose minocycline product FDA-approved for treating inflammatory lesions of rosacea in adults; demonstrated superiority over Oracea and placebo in Phase 3 clinical trials (62.7% IGA treatment success vs 39.0% for Oracea, p<0.001).
• Qbrexza Prescription medication for treating primary axillary hyperhidrosis (excessive underarm sweating) in patients 9 years of age and older.
• Accutane
• Amzeeq
• Zilxi
• Luxamend
• Exelderm
• Targadox

Quantifiable outcome

• Emrosi achieved 62.7% Investigator's Global Assessment treatment success vs 39.0% for Oracea (p<0.001)
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators10 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Sun Pharmaceutical Industries: Sun Pharma is one of the largest generic and specialty pharmaceutical companies globally with a meaningful dermatology presence (including Tildrakizumab and a broad generic dermatology portfolio), broadly comparable as a large dermatology commercializer, though much larger and more diversified than Journey Medical.
• Galderma Holding AG: Galderma is the world's largest pure-play dermatology company, offering a broad portfolio of prescription and consumer skin care products. It is comparable to Journey Medical as a leading dermatology prescription drug commercializer, though at materially greater scale and global reach.
• Organon & Co. Organon is a global specialty pharmaceutical company with a meaningful dermatology presence following its Dermavant acquisition, offering comparable commercial-stage dermatology products and prescriber-focused sales infrastructure, though at larger scale.
• Almirall S.A. Almirall is a European-headquartered specialty pharmaceutical company with a focused dermatology franchise, comparable to Journey Medical in therapeutic emphasis though at significantly larger scale and with broader geographic coverage.
• Pfizer Inc. Pfizer is a global pharmaceutical incumbent with an extensive dermatology and inflammation portfolio (e.g., Cibinqo, Eucrisa, Litfulo), broadly comparable as a prescription dermatology commercializer addressing overlapping conditions such as atopic dermatitis and rosacea, though at massive scale.

Direct peers

• Verrica Pharmaceuticals: Verrica Pharmaceuticals is a small dermatology-focused commercial-stage pharmaceutical company developing and commercializing prescription treatments for skin diseases, directly comparable to Journey Medical in therapeutic focus (dermatology), business model (single-vendor specialty pharma), and scale.
• Biofrontera AG: Biofrontera is a specialty dermatology pharmaceutical company commercializing prescription treatments for skin diseases, with similar scale, dermatology-only focus, and direct-to-dermatologist sales model as Journey Medical.

Emerging players

• Dermavant Sciences: Dermavant Sciences is a dermatology-focused biopharmaceutical company (now owned by Organon) developing topical prescription therapies for skin conditions including psoriasis and atopic dermatitis, comparable to Journey Medical in its dermatology focus and small-cap commercial/scale-up phase.
• Sol-Gel Technologies: Sol-Gel Technologies is a small dermatology-focused pharmaceutical company developing and commercializing topical prescription treatments for skin diseases, comparable to Journey Medical in niche dermatology focus and small-cap scale.
• MC2 Therapeutics: MC2 Therapeutics is a small dermatology-focused company developing topical therapies for skin conditions, comparable to Journey Medical in specialty dermatology positioning and commercial-stage or near-commercial profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/journey-medical-corporation-a-subsidiary-of-coronado-biosciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Journey Medical